1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Determining Whether to Submit an ANDA or a 505(b)(2) Application
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Determining Whether to Submit an ANDA or a 505(b)(2) Application August 2026

Download the Draft Guidance Document Read the Federal Register Notice
Draft Level 1 Guidance

Not for implementation. Contains non-binding recommendations.

Docket Number:
FDA-2017-D-5974
Issued by:
Guidance Issuing Office
Center for Drug Evaluation and Research

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry titled “Determining Whether to Submit an ANDA or a 505(b)(2) Application.” This draft guidance is intended to serve as a foundational guidance to assist applicants in determining which one of the abbreviated approval pathways under the Federal Food, Drug, and Cosmetic Act (FD&C Act) is appropriate for the submission of a marketing application to FDA. This draft guidance revises the guidance for industry titled “Determining Whether to Submit an ANDA or a 505(b)(2) Application” issued in May 2019 and, when finalized, will replace the 2019 guidance for industry.

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2017-D-5974.

Back to Top